Table 1.
Patient characteristics
| Characteristic | Cohort 2 N = 25 |
Cohort 3 N = 31 |
|---|---|---|
| Male | 16 (64.0) | 19 (61.3) |
| Age, median (range) (years) | 64 (21–82) | 62 (32–75) |
| Race | ||
| Asian | 17 (68.0) | 15 (48.4) |
| White | 8 (32.0) | 16 (51.6) |
| Region | ||
| United States | 3 (12.0) | 12 (38.7) |
| East Asia | 16 (64.0) | 13 (41.9) |
| Rest of world | 6 (24.0) | 6 (19.4) |
| ECOG performance status | ||
| 0 | 15 (60.0) | 14 (45.2) |
| 1 | 10 (40.0) | 17 (54.8) |
| Metastatic stage | ||
| M0 | 1 (4.0) | 5 (16.1) |
| M1 | 24 (96.0) | 26 (83.9) |
| Prior surgery for gastric cancer | 5 (20.0) | 12 (38.7) |
| Histology, WHO classification | ||
| Tubular adenocarcinoma | 22 (88.0) | 25 (80.6) |
| Signet ring cell carcinoma | 2 (8.0) | 3 (9.7) |
| Mixed carcinoma | 1 (4.0) | 2 (6.5) |
| Other poorly cohesive carcinoma | 0 | 1 (3.2) |
| PD-L1 expression | ||
| CPS ≥ 1 | 16 (64.0) | 31 (100.0) |
| CPS < 1 | 8 (32.0) | 0 |
| Unknown | 1 (4.0) | 0 |
Unless otherwise indicated, all data are n (%)
CPS combined positive score, ECOG Eastern Cooperative Oncology Group, PD-L1 programmed death ligand 1, WHO World Health Organization